← Human Trials & Peer-Reviewed Studies
Insulin Resistance Negatively Influences the Muscle-Dependent IGF-1-Bone Mass Relationship in Premenarcheal Girls
Plain-language guide to PMID 26574958 (2016): double-blind randomized controlled trial study of IGF-1 LR3 in 147 girls, insulin resistance, prediabetes & type 2 diabetes.
Key Facts
- PMID
- 26574958
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 2016
- Study type
- Randomized Controlled Trial
- Authors
- Kindler JM et al. (8 authors)
- DOI
- 10.1210/jc.2015-3451
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of IGF-1 LR3 in the context of insulin resistance, prediabetes & type 2 diabetes, published as a randomized controlled trial.
The researchers sought to determine the effect of insulin resistance on the muscle-dependent relationship between IGF-1 and bone mass in premenarcheal girls.
Why It Was Studied
IGF-1 promotes bone growth directly and indirectly through its effects on skeletal muscle.
Insulin and IGF-1 share a common cellular signaling process; thus, insulin resistance may influence the IGF-1-muscle-bone relationship.
Who Took Part
The abstract describes 147 girls taking part.
PubMed indexes the participants as children, women only.
How the Study Was Run
The researchers set it up as a randomized and double-blind study.
The girls were allocated by chance, so the IGF-1 LR3 group and the comparison group should start out alike.
As a double-blind IGF-1 LR3 study, the assignments were hidden from both participants and investigators until the end.
This was a cross-sectional study conducted at a university research center involving 147 girls ages 9 to 11 years.
What Was Measured
The subject headings attached to it are Absorptiometry, Photon, Blood Glucose, Body Composition, Body Height, Bone Density, Cross-Sectional Studies and Insulin.
What This Means in Plain Language
The paper is a randomized and double-blind study of IGF-1 LR3 in 147 girls in people with insulin resistance, prediabetes & type 2 diabetes.
Results are reported in around 10 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2016 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the IGF-1 LR3 compound page, Insulin resistance, prediabetes & type 2 diabetes research.
Our Notes on the Compound
IGF-1 LR3: A modified IGF-1 analog that escapes binding proteins, so it stays active ≥24 h.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.